Faeth Therapeutics (FTH) Non-Current Assets (2020 - 2026)

Faeth Therapeutics (FTH) has reported Non-Current Assets for 7 consecutive years, with -$43.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 46.33% year-over-year to -$43.3 million; the trailing twelve-month figure through Jun 2026 stood at -$38.9 million (up 31.31% YoY), and the FY2025 full-year result was $1.4 million, down 59.35% from the prior year.
• Non-Current Assets slipped to -$43.3 million in Q2 2026 per FTH's latest filing, from $1.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $11.1 million in Q1 2022 and bottomed at -$43.3 million in Q2 2026.
• Historically, Non-Current Assets has averaged -$487833.3 across 5 years, with a median of $6.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 554.11% in 2022, then plunged 652.27% in 2025.
• Over 5 years, Non-Current Assets stood at $9.8 million in 2022, then fell by 27.2% to $7.1 million in 2023, then plunged by 51.82% to $3.4 million in 2024, then slumped by 59.35% to $1.4 million in 2025, then sank by 3202.08% to -$43.3 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered -$43.3 million, $1.1 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.